Raymond James Reiterates Buy Rating on Aktis Oncology
Raymond James maintains its optimistic outlook on Aktis Oncology with a $40 target, a 63.67% upside from the current price.
Key Points
- Raymond James reiterated its buy rating on Aktis Oncology, Inc. (AKTS) with a $40 price target on June 16, 2026.
- Raymond James's $40 price target implies 63.67% upside from Aktis Oncology, Inc.'s ($AKTS) current $24.44 share price.
- Shares of NasdaqGS:AKTS are trading around $22.06, with a market cap of approximately $1.14 billion.
- Aktis Oncology is a clinical-stage biotech firm focused on radiopharmaceuticals, headquartered in Boston, MA.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Raymond James has reiterated its buy rating on Aktis Oncology, Inc. (NasdaqGS:AKTS) with a price target of $40. This reaffirmation by analyst Christopher Raymond was made on June 16, 2026, as the shares of Aktis traded around $22.06.
Aktis Oncology, Inc. Stock Down 5.2%
Shares of Aktis Oncology are currently trading near $22.06. The company, which operates in the biotechnology sector, boasts a market capitalization of about $1.14 billion. Although it is not yet profitable, it has a forward P/E ratio of -10.39. The stock has seen a 52-week low of $14.72 and a high of $29.16, with moving averages of $19.30 over 50 days and $19.32 over 200 days. Its current and quick ratios are both robust at over 19, indicating strong liquidity, while its debt-to-equity ratio stands at 2.29.
Analysts Set New Price Targets
On June 16, 2026, Raymond James initiated coverage on Aktis Oncology with a buy rating and a $40 price target. Earlier in the month, HC Wainwright & Co. maintained its buy rating, setting a $35 price target on June 2. The consensus among analysts is strong, with a mean target price of $32.65 and a recommendation of strong buy from five analyst opinions.
Other Institutional Activity in Aktis Oncology
MPM Bioimpact LLC has a significant stake in Aktis Oncology, holding 4,835,872 shares valued at approximately $86.5 million. Similarly, ECOR1 Capital, LLC owns 4,824,469 shares worth about $86.3 million. Blue Owl Capital Holdings LP holds 3,161,348 shares valued at around $56.6 million. Wellington Management Group LLP and T. Rowe Price Investment Management, Inc. also have substantial positions, owning 2,317,044 and 2,123,812 shares, respectively, with values over $41 million and $37.9 million. BlackRock, Inc. rounds out the list with 2,112,127 shares, valued at nearly $37.8 million.
Insider Buying and Selling at Aktis Oncology, Inc.
Recent insider transactions include Glenn Gormley buying 37,866 shares on April 15, 2026. Todd Foley made several transactions on January 12, 2026, including purchasing 4,002,533 shares and selling 10,227,273 shares. Ansbert Gadicke and MPM Bioventures 2018, L.P. also sold 5,000,000 and 6,000,000 shares, respectively, on the same day.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts. It focuses on developing targeted radiopharmaceuticals for the treatment of solid tumor cancers. The company is led by CEO Dr. Matthew Roden and employs 79 people. Aktis is currently advancing its lead product candidate, [225Ac]Ac-AKY-1189, through clinical trials aimed at treating Nectin-4 expressing solid tumors.
Bottom Line
Raymond James' reiteration of its buy rating and the $40 price target reflects confidence in Aktis Oncology's potential. While 13F filings and analyst ratings provide valuable insights, they are historical and should be considered as part of a broader investment strategy. Aktis Oncology continues to be a company to watch in the biotech sector, especially with its focus on innovative cancer treatments.
Get Aktis Oncology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AKTS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.